Answers are grounded in this paper and cite their sources.
Analysis shows COVID-19 did not worsen sinonasal symptoms in patients with chronic polypous rhinosinusitis and AERD.
chronic rhinosinusitis (CRS) is a prevalent disease affecting 5-15% of the population, characterized by prolonged inflammation of the mucosa of the paranasal sinuses. Chronic rhinosinusitis with nasal polyps (CRSwNP) accounts for approximately 18-20% of all CRS cases and has a more severe clinical course compared to CRS without nasal polyps (CRSsNP). A particular group of patients includes those with CRSwNP associated with aspirin-exacerbated respiratory disease (AERD), which comprises asthma, rhinosinusitis with polyps, and intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). This study aimed to evaluate the impact of a past COVID-19 infection on sinonasal symptoms and quality of life in patients with chronic polypous rhinosinusitis and aspirin triad based on the analysis of SNOT-22 questionnaire scores and endoscopic assessment results using the Lund-Kennedy scale. The study was conducted among outpatients at the clinic of the State Institution " O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Sciences of Ukraine." Sixty patients aged 18 to 75 years with a diagnosis of chronic polypous rhinosinusitis with NSAID intolerance were selected and divided into two groups: Group 1 (17 patients) who did not have COVID-19 and Group 2 (43 patients) who had a history of COVID-19. Group 2 was further divided into two subgroups: Subgroup 2A (18 patients, who reported no impact of COVID-19 on the course of CRS) and Subgroup 2B (25 patients, who reported a subjective worsening of CRS after COVID-19). A survey was conducted using the SNOT-22 questionnaire, and endoscopic examination of the nasal cavity was performed with assessment using the Lund-Kennedy scale. The analysis of the SNOT-22 results showed that the mean scores in Group 1 were 41.9 ± 17.94, and in Group 2, they were 43.62 ± 20.12, with no statistically significant differences (p=0.812). The mean scores in Subgroups 2A and 2B were 44.3 ± 19.4 and 43.0 ± 21.2, respectively, also with no statistically significant differences (p=0.874). The endoscopic assessment using the Lund-Kennedy scale did not reveal significant differences between the groups (p=0.588). The study results indicate that a past COVID-19 infection did not have a statistically significant impact on sinonasal symptoms in patients with chronic polypous rhinosinusitis and aspirin triad. COVID-19 did not lead to a significant worsening of the clinical course of the disease, warranting further studies to explore the virus's impact on other aspects of respiratory health in patients with AERD.
No takes yet. Share an insight, caveat, or question.
Moldovanov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: